21 November 2017
News and Views
Links and Services
A study in the latest issue of the Journal of Hepatology identifies baseline characteristics that predict the outcomes of long-term telbivudine treatment of chronic Hepatitis B.
In the GLOBE trial, telbivudine treatment was identified as a significant, independent predictor
Email this page to a colleague
GastroHep.com is a Blackwell Publishing registered trademark
© 2017 Wiley-Blackwell and GastroHep.com and contributors